This pharma stock has risen over 170% in 17 months
Next week, on Thursday, May 23, Merck will turn ex-dividend for Rs 440 per share, which includes a one-time special dividend of Rs 416 per share on account of gain on business transfer.
 "This pharma stock has risen over 170% in 17 months")
premium
Procter & Gamble Health (formerly Merck) shares were trading higher for the sixth straight day, up 4 per cent in early morning trade at Rs 4,389, also its new high on the BSE, after the company reported strong net profit growth in March quarter (Q1CY19).
The pharmaceutical company’s profit after tax rose 79 per cent at Rs 40.7 crore in Q1CY19 driven by high interest income and operational efficiencies. Total revenue grew 22.2 per cent at Rs 249 crore against Rs 204 crore in previous year quarter. The strong revenue growth driven by a strong performance across brands, growth in exports, higher interest income and improved execution.
The management said with a brand portfolio backed by science and trusted by doctors, pharmacists and consumers, and the best of consumer health capabilities and cultures, the company was working towards creating a much stronger presence in India's fast-growing consumer health industry.
Last year, Procter & Gamble successfully acquired Merck’s consumer health business globally and in India.
Procter & Gamble Health is one of India's largest vitamins, minerals and supplements (VMS) companies that manufactures and markets over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life.
Thus far in the current calendar year 2019, the market price of Merck has rallied 42 per cent on the BSE. In comparison, the S&P BSE Sensex was up 4 per cent, while the S&P BSE Healthcare slipped 5 per cent during the same period.
In previous entire calendar year 2018, the stock zoomed 133 per cent, against 7 per cent rise in the benchmark index and 6 declined in the pharma sector index.
Next week, on Thursday, May 23, 2019, the stock of Merck will turn ex-dividend for Rs 440 per share.
The company’s board, on February 27, had declared a dividend of Rs 440 per share for the financial year ended December 31, 2018, which includes a one-time special dividend of Rs 416 per share on account of gain on business transfer of biopharma, performance materials and life sciences (BPL business).
Post the divestment of its low margin business, the company is left mainly with consumer products (OTC) and vitamins, which have strong positioning domestic market (key brands – Neurobion, Evion, Livogen, Polybion etc.).
The pharmaceutical company’s profit after tax rose 79 per cent at Rs 40.7 crore in Q1CY19 driven by high interest income and operational efficiencies. Total revenue grew 22.2 per cent at Rs 249 crore against Rs 204 crore in previous year quarter. The strong revenue growth driven by a strong performance across brands, growth in exports, higher interest income and improved execution.
The management said with a brand portfolio backed by science and trusted by doctors, pharmacists and consumers, and the best of consumer health capabilities and cultures, the company was working towards creating a much stronger presence in India's fast-growing consumer health industry.
Last year, Procter & Gamble successfully acquired Merck’s consumer health business globally and in India.
Procter & Gamble Health is one of India's largest vitamins, minerals and supplements (VMS) companies that manufactures and markets over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life.
Thus far in the current calendar year 2019, the market price of Merck has rallied 42 per cent on the BSE. In comparison, the S&P BSE Sensex was up 4 per cent, while the S&P BSE Healthcare slipped 5 per cent during the same period.
In previous entire calendar year 2018, the stock zoomed 133 per cent, against 7 per cent rise in the benchmark index and 6 declined in the pharma sector index.
Next week, on Thursday, May 23, 2019, the stock of Merck will turn ex-dividend for Rs 440 per share.
The company’s board, on February 27, had declared a dividend of Rs 440 per share for the financial year ended December 31, 2018, which includes a one-time special dividend of Rs 416 per share on account of gain on business transfer of biopharma, performance materials and life sciences (BPL business).
Post the divestment of its low margin business, the company is left mainly with consumer products (OTC) and vitamins, which have strong positioning domestic market (key brands – Neurobion, Evion, Livogen, Polybion etc.).
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%